Shire Shores Up Rare Disease Portfolio With Amicus Compounds
Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.
Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.